GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mycenax Biotech Inc (ROCO:4726) » Definitions » Capex-to-Operating-Cash-Flow

Mycenax Biotech (ROCO:4726) Capex-to-Operating-Cash-Flow : 8.80 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Mycenax Biotech Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Mycenax Biotech's Capital Expenditure for the three months ended in Sep. 2024 was NT$-60.72 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2024 was NT$6.90 Mil.

Hence, Mycenax Biotech's Capex-to-Operating-Cash-Flow for the three months ended in Sep. 2024 was 8.80.


Mycenax Biotech Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Mycenax Biotech's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mycenax Biotech Capex-to-Operating-Cash-Flow Chart

Mycenax Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.51 - - -

Mycenax Biotech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.92 - - 1.32 8.80

Competitive Comparison of Mycenax Biotech's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Mycenax Biotech's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mycenax Biotech's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mycenax Biotech's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Mycenax Biotech's Capex-to-Operating-Cash-Flow falls into.



Mycenax Biotech Capex-to-Operating-Cash-Flow Calculation

Mycenax Biotech's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-297.602) / -131.178
=N/A

Mycenax Biotech's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-60.715) / 6.903
=8.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mycenax Biotech  (ROCO:4726) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Mycenax Biotech Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Mycenax Biotech's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Mycenax Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.66, Shengyi 2nd Road, 7th Floor, Hsinchu Science Park, Hsinchu County, Zhubei, TWN, 302041
Mycenax Biotech Inc is a Taiwan-based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company provides services for program evaluation/confirmation, cell line development, and construction, process development technology platforms, drug characterization analysis, the establishment of testing methods, and drug production in accordance with PIC/S GMP manufacturing standards.

Mycenax Biotech Headlines

No Headlines